Cancer Clinical Trial
Official title:
Pilot Study of Mindfulness-Based Stress Reduction for Patients With Persistent Cancer-Related Fatigue
Verified date | November 2010 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purposes of the proposed study are (1) to collect data on the feasibility of offering
Mindfulness-Based Stress Reduction (MBSR) as an intervention to reduce fatigue and
psychological distress in cancer patients who are not in active treatment for their cancer
and (2) to estimate effect sizes of the intervention for fatigue, depression, anxiety, and
sleep disturbance. The investigators also will obtain preliminary effect sizes of the degree
to which the intervention increases mindfulness, and the investigators will evaluate dosage
effects. Findings will suggest whether a future randomized controlled trial with
cancer-related fatigue (CRF) as the primary outcome is feasible and warranted.
Participants will be randomly assigned to either the MBSR intervention arm or to a wait-list
control arm. The MBSR intervention will consist of a weekly 2-hour class to be held for
seven consecutive weeks in the Indiana University Simon Cancer Center Pavilion; the class on
week six will be extended to a 3-hour "retreat." Participants will be invited to engage in
daily home practice of meditation and other mindfulness exercises. All participants will
complete a series of self-report questionnaires prior to the start of the classes,
immediately following the end of classes, and 1 month after the class ends. Those in the
intervention arm will begin the MBSR class the week after enrollment; the control group will
be offered the same 7-week program after 1-month post-intervention follow-up assessments are
completed—approximately 13 weeks after enrollment.
Primary Aim 1: Obtain preliminary RCT effect sizes for changes in fatigue of an MBSR
treatment group compared to a wait-list control group.
Hypothesis 1: Immediately post-intervention (T2), improvements in fatigue compared to
pre-intervention (T1) will be greater in the treatment group than the control group.
Hypothesis 2: At 1 month post intervention (T3), improvements in fatigue compared to
pre-intervention (T1) will be greater in the treatment group than improvements in the
control group.
Status | Completed |
Enrollment | 35 |
Est. completion date | October 2010 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Individuals will be eligible to participate based on the following criteria: 1. they have a cancer diagnosis 2. are age 18 or older 3. have clinically significant cancer-related fatigue (CRF) that has persisted for the previous 8 weeks or longer. Clinically significant CRF will be defined by a cutoff mean score of = 4 across the 3-item Fatigue Symptom Inventory severity composite. Exclusion Criteria: - Participants will be excluded based on the following criteria: 1. chemotherapy, biologic response modifiers, radiation therapy, or surgery in prior 3 months 2. enrollment in hospice care 3. severe hearing impairment 4. severe depression (PHQ-8 = 15) 5. past participation in a mindfulness meditation class 6. incapable of reading and writing English. Each of these characteristics will be assessed as part of the eligibility screening interview. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Indiana University | National Cancer Institute (NCI), Walther Cancer Institute |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fatigue Symptom Inventory Interference Subscale | Last 7 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|